Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast cancer in the adjuvant setting.
Multiple myeloma (MM) accounts for 19 % of hematologic malignancies diagnosed in the United States and has a higher incidence in older adults [1]. Treatment decision-making…
A clinical trial of yttrium-90–FF-21101 directed against P-cadherin did not meet predefined efficacy criteria. Because imaging studies indicated FF-21101 uptake by tumors, other warheads combined…
Researchers explain how precision medicine, immunotherapy, AI, treating blood cancers, and addressing cancer disparities may advance in 2025.
A new generation of drugs and drug combinations are improving the outlook for patients with endometrial (uterine) cancer.
Rachel Darwin, Senior Manager, Public Relations Two-day symposium in Riyadh, Saudi Arabia brings together leading oncology professionals from across the MENA region to review updated…
Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.
The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck squamous cell carcinoma undergoing radiotherapy with contraindications…
A 68-year-old woman with a history of discoid lupus erythematosus presented with multiple subcutaneous nodules on the breast and upper extremities. An incisional biopsy was…
Key PointsB-PLL has a differential DNA methylation signature compared with CLL, MCL, and SMZL.Identification of 2 potential B-PLL subtypes with different b
The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.
